Most Read Articles
Dr. Joseph Delano Fule Robles, 06 May 2019

Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.

Roshini Claire Anthony, 30 Apr 2019

Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.

Cancer progression common in men who undergo deferred prostatectomy

11 Sep 2018
Prostate cancer is a silent killer. Many may not be aware of the illness until it is too late.

Despite active surveillance, cancer progression appears to be common in men who undergo deferred radical prostatectomy (RP), according to a recent study.

The study included 132 men with screening-detected prostate cancer (median age 64 years) who received radical prostatectomy following active surveillance. Radical prostatectomy was performed upon detection of disease progression or patient request. Active surveillance included prostate-specific antigen (PSA) tests every 3–6 months and biopsies every 2–4 years.

The median time from prostate cancer diagnosis to RP was 1.9 years, during which the participants received a median of one repeat biopsy for active surveillance.

At deferred RP, 52 patients (39 percent) showed at least one unfavourable pathology in the RP specimen. For instance, 35 percent (n=46) of the participants demonstrated an increase in Gleason score (GS) from diagnostic biopsy. Twelve men (9.1 percent) had GS >3+4.

Moreover, 22 percent (n=29) were positive for extraprostatic extensions, 3.0 percent (n=4) had seminal vesicle invasion, 22 percent (n=29) demonstrated positive surgical margins, and 0.8 percent (n=1) had positive lymph nodes. The median tumour volume was 0.70 mL.

PSA relapse was reported in 25 men, 10 of whom underwent salvage radiation. The resulting 10-year PSA relapse-free survival was 79.5 percent.

At the time of diagnostic biopsy, 29 percent (n=38) of the patients had unidentifiable index tumours. At the last repeat biopsy before the deferred surgery, index tumour was not identified in 22 participants (21 percent).

Clinicians can use the findings in counselling prostate cancer patients who choose to undergo active surveillance and deferred RP, researchers said, adding that there is a need to improve the detection of cancer progression during active surveillance.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Joseph Delano Fule Robles, 06 May 2019

Gilteritinib, a novel inhibitor of the tyrosine kinase FLT3, improves survival outcomes among patients with relapsed or refractory acute myeloid leukaemia (AML) with FLT3 mutations vs standard chemotherapy, according to results of the phase III ADMIRAL trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2019 held in Atlanta, Georgia, US.

Roshini Claire Anthony, 30 Apr 2019

Patients with advanced small cell lung cancer (SCLC) who experience disease progression despite two or more lines of therapy could benefit from pembrolizumab in the third-line setting, according to results from the phase 1b KEYNOTE-028 and phase II KEYNOTE-158* studies presented at AACR 2019.